Drugs / T-1101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04685473 | Jan 2021 → Apr 2025 | refractory malignant neoplasm | Taivex Therapeutics Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03195764 | Sep 2017 → Oct 2019 | refractory malignant neoplasm | Taivex Therapeutics Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT03349073 | Sep 2017 → Jun 2019 | refractory malignant neoplasm | Taivex Therapeutics Corporation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-07-22 | Taivex Therapeutics Corporation | Results T-1101 Accepted for Poster Presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, Highlighting Clinical Promise and Global Recognition taivex.com ↗
The poster will present results from the Phase I clinical trial, which demonstrated favorable safety and tolerability, along with preliminary signs of clinical activity. |
| 2025-05-19 | Taivex Therapeutics Corporation | Regulatory T-1101 Receives TFDA Approval for Phase II Clinical Trial, Advancing Development Milestone taivex.com ↗
Taivex announced that its investigational drug T-1101 has received approval from Taiwan’s Food and Drug Administration (TFDA) to initiate Phase II clinical trials. |
| 2025-04-08 | Taivex Therapeutics Corporation | Results T-1101 Accepted for Online Publication at the 2025 ASCO Annual Meeting, Showcasing Innovative Mechanism and Clinical Potential taivex.com ↗
The accepted abstract presents result from the Phase I clinical trial, which demonstrated favorable safety and tolerability, along with preliminary signs of clinical activity. |
| 2025-01-20 | Taivex Therapeutics Corporation | Regulatory T-1101 Receives FDA Approval to Advance to Phase II Clinical Trial, Marking a Significant Milestone taivex.com ↗
Taivex announced that T-1101 has received approval from the U.S. Food and Drug Administration (FDA) to advance to Phase II clinical trials. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-22 | Taivex Therapeutics Corporation | T-1101 Accepted for Poster Presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, Highlighting Clinical Promise and Global Recognition taivex.com ↗ |
| 2025-05-19 | Taivex Therapeutics Corporation | T-1101 Receives TFDA Approval for Phase II Clinical Trial, Advancing Development Milestone taivex.com ↗ |
| 2025-04-08 | Taivex Therapeutics Corporation | T-1101 Accepted for Online Publication at the 2025 ASCO Annual Meeting, Showcasing Innovative Mechanism and Clinical Potential taivex.com ↗ |
| 2025-01-20 | Taivex Therapeutics Corporation | T-1101 Receives FDA Approval to Advance to Phase II Clinical Trial, Marking a Significant Milestone taivex.com ↗ |
| 2024-11-28 | Taivex Therapeutics Corporation | Taivex’s ‘s T-1101 and T-1201 Invited to Present Study Progress at KSMO 2024 Annual Meeting taivex.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03195764 ↗ |
| Known as | T-1101 (Tosylate) | “T-1101 (Tosylate) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by Taivex Therapeutics Corp.” NCT03195764 ↗ |
| Modality | Small molecule | “T-1101 (Tosylate) is a new small molecule chemical entity” NCT04685473 ↗ |
| Route | Oral | “oral administration of T-1101 (Tosylate)” NCT03195764 ↗ |